Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia

Sleep

Volumn 34, Issue 10, 2011, Pages 1433-1442

  Krystal, Andrew D ^a   Lankford, Alan ^b   Durrence, H Heith ^c   Ludington, Elizabeth ^c   Jochelson, Philip ^d   Rogowski, Roberta ^c   Roth, Thomas ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sleep Disorders Center of Georgia   (United States)

^c Somaxon Pharmaceuticals Inc   (United States)

^d BrainCells Inc   (United States)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

Chronic insomnia; Doxepin; Early morning awakenings; Sleep maintenance insomnia; TST; WASO; WTDS

Indexed keywords

DOXEPIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP QUALITY; SLEEP STAGE; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DOXEPIN; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053464014     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/SLEEP.1294     Document Type: Article

References (30)

1. Lichstein KL, Durrence HH, Taylor DJ, et al. Epidemiology of sleep: age, gender, and ethnicity. Mahwah, NJ: Erlbam, 2004
2. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 2004;39:411-8
3. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997;31:333-46 (Pubitemid 27379854)
4. Buysse D, Reynolds CF III, Kupfer DJ, et al. Effects of diagnosis on treatment recommendations in chronic insomnia-a report from the APA/NIMH DSM-IV field trial. Sleep 1997;20:542-52 (Pubitemid 27415477)
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 1997.
6. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
7. Edinger JD, Bonnet M, Bootzin RR, et al. Derivation of research diagnostic criteria for insomnia: Report on an American Academy of Sleep Medicine work group. Sleep 2004;27:1567-96. (Pubitemid 40041627)
8. Hohagen F, Kappler C, Schramm E, et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4 (Pubitemid 24317744)
9. Ohayon MM, Krystal A, Roehrs TA, Roth T, Vitiello MV. Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med. 2010;11:236-41.
10. Ohayon MM, Roth T. What are the contributing factors for insomnia in the general population? J Psychosom Res 2001;51:745-755 (Pubitemid 34055801)
11. Lu J, Greco MA. Sleep circuitry and the hypnotic mechanism of GABAA drugs. J Clin Sleep Med 2006;2:S19-S26 (Pubitemid 43893280)
12. Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther 2006;112:612-29 (Pubitemid 44573490)
13. Patat A, Paty I, Hindmarch I. Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol 2001;16:369-92. (Pubitemid 32747103)
14. McQuade R, Creton D, Stanford SC. Effect of novel environmental stimuli on rat behaviour and central noradrenaline function measured by in vivo microdialysis. Psychopharmacology (Berl) 1999;145:393-400. (Pubitemid 29424534)
15. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23:3555-60. (Pubitemid 36531999)
16. Roth T, Zorick F, Wittig R, et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 1982;43:366-8 (Pubitemid 12019212)
17. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63 (Pubitemid 32717879)
18. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry 1996;29:187-92 (Pubitemid 26315670)
19. Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology 2003;170:423-8.
20. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1, 3 and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-61 (Pubitemid 350036981)
21. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1, 3 and 6 mg in elderly patients with primary insomnia. J Clin Psych 2008;69:1557-64
22. Krystal A, Durrence H, Scharf M, et al. Long-term efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61.
23. Roth T, Durrence H, Jochelson P, et al. Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 2010;11:843-7.
24. Rechtschaffen A, Kales A, eds. Manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles, CA: Brain Information Service/Brain Research Institute, UCLA; 1968
25. Wechsler DA. Manual for the Wechsler Adult Intelligence Scale. New York: The Psychological Corporation; 1955
26. Tyrer P, Murphy S, Riley P. The benzodiazepine withdrawal symptom questionnaire. J Affect Disord 1990;19:53-61 (Pubitemid 20141161)
27. Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406.
28. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.Curr Med Res Opin 2004;20:1979-91. (Pubitemid 40179637)
29. Tuomisto L, Tuomisto J. Diurnal variations in brain and pituitary histamine and histamine-N-methyltransferase in the rat and guinea pig. Med Biol 1982;60:204-9. (Pubitemid 13253965)
30. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.) Lawrence Erlbaum Associates, 1988.